Navigation Links
NSAIDs Won't Shield Against Skin Cancer
Date:2/15/2010

ing the study. Specifically, 48 percent said they had used aspirin, 18 percent ibuprofen, 5 percent naproxen (ie, Aleve), and 4 percent nabumetone (Relafen).

But regardless of dosage used, type of medication taken, and/or whether NSAIDs were pharmacy-dispensed, the anti-inflammatory drugs were not found to be associated with a drop in skin cancer risk.

In fact, those patients who had taken NSAIDs for a relatively short period of time --anywhere from one to three years-- actually appeared to have a slightly increased risk for developing squamous cell carcinoma, the researchers said.

They concluded that NSAIDs did not seem to offer any protective effect with respect to skin cancer, and -- given the potential toxic side-effects of long-term NSAID use -- they suggested that patients at higher risk for skin cancer should be directed towards other safer, and perhaps more effective, interventions.

"We were surprised at the lack of NSAID protection," Asgari remarked. "Particularly when we saw an increased risk for skin cancer associated with the short-term use of NSAIDs. But actually that's not been unheard of, and I think there could be various explanations for this. Maybe people using NSAIDs short-term have other co-morbidities that make them more prone to having a weaker immune system and having poorer health. And also there are some forms of NSAIDs that do make you sun-sensitive, and more prone to getting DNA damage. That might be another explanation. But we were surprised."

However, Eric Jacobs, strategic director of pharmaco-epidemiology for the American Cancer Society, said Asgari's findings were not surprising.

"Results from this study are consistent with those of most previous studies," he said. "The best way to lower the risk of non-melanoma skin cancer, including squamous cell carcinoma, is to limit your exposure to strong sunlight -- for example by wearing a hat and using sunscreen -- and to avoid using
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Early Use of NSAIDs Might Prevent Alzheimers
2. NSAIDs Might Lower Breast Cancer Risk
3. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
4. NSAIDs No Better for Low Back Pain
5. NSAIDs Protect Against Parkinsons Disease
6. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
7. Using coxibs and NSAIDs to treat osteoarthritis
8. Strict Blood Sugar Lowering Wont Ease Diabetes Heart Risk
9. Blue Cross and Blue Shield Association Expands Blue Distinction(R) Designation to Include Spine Surgery, Knee and Hip Replacement
10. Blue Cross and Blue Shield of Illinois Offers BlueCare Dental Plan
11. Blue Cross Blue Shield of Massachusetts Urges Members to Get Their Flu Shot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated ... national survey by researchers at the University of Michigan ... under the age of 18 at home, and adults ... than other adults to support universal coverage of birth ... the Journal of the American Medical Association ...
(Date:4/22/2014)... has been approved since November 2013 for the prevention ... In an early benefit assessment pursuant to the "Act ... (AMNOG), the German Institute for Quality and Efficiency in ... offers an added benefit over the appropriate comparator therapy. ... of turoctocog alfa is not proven. As no relevant ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
Breaking Medicine News(10 mins):Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... of a multi-faceted transcriptional complex to control of ... stem cells. Two separate studies, published by Cell ... Cell, provide insight into novel subunits associated with ... a previously undescribed chromatin function that is required ...
... M.D., Will Lead One of the Nation,s Largest ... Electrophysiology Programs, ... and Director of Cardiac Electrophysiology at,Washington University in St. Louis, has ... Institute., "We are pleased to have such an established leader ...
... largest,provider of business services to orthodontic and dental ... and Atlanta, Georgia to,better serve the company,s practices ... confirm our operating principle that the,heart of our ... in the,hundreds of practices we serve each day," ...
... 11% of international disease burden , , THURSDAY, Jan. 17 ... childhood malnutrition accounts for more than one-third of childhood ... researchers report. , "The key messages here are that ... reform is needed," lead researcher Dr. Robert Black, a ...
... adopt the World Health Organization (WHO) standard on fine particulate ... premature deaths, concludes research in the Journal of Epidemiology and ... levels of fine particulate matter pollution (PM2.5) at 20 g/m ... by the US Environmental Protection Agency is 15 g/m ...
... London, New Delhi and Singapore (January 17, 2008) ... looks set to continue its successful growth in ... partnership with the International Union for Health Promotion ... Promotion & Education. , Published quarterly, Promotion and ...
Cached Medicine News:Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3Health News:Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology 2Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 3Health News:Europe should adopt WHO recommendations for particulate matter cuts 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Morria Biopharmaceuticals Plc, a,biopharmaceutical company focused ... announced that it has obtained regulatory,approval from ... to initiate,a Phase II study of MRX-4 ... The two-arm, randomized, multi-dose, double-blind, placebo-controlled,study includes ...
... Md., June 11 EntreMed, Inc.,(Nasdaq: ENMD ... treatment of cancer and inflammatory diseases, today,announced the ... of 2-,methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter,and ... for analogs,of 2ME2 in oncology and a broad ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3
... The Genesis II® Total Knee System will ... far more is possible with less - ... while fully addressing both clinical and cost ... these design goals, giving surgeons creative solutions ...
Cementless hip system...
... system continues the "Consensus Concept" approach ... with the diversified experience of a ... an affordable knee system that incorporates ... designed to provide both joint and ...
... Foundation® Modular Revision System offers a femoral ... specially designed cam action that engages at ... smooth stable femoral roll-back motion and allow ... tibial insert in conjunction with the femur ...
Medicine Products: